Research Reports | Market Assessment
October 2015

Nonalcoholic Steatohepatitis (NASH) | Niche and Rare Pharmacor | G7 | 2015

Nonalcoholic fatty liver disease (NAFLD) is caused by a buildup of fat in the liver. A proportion of NAFLD sufferers will also experience injury to their hepatocytes, which can lead to nonalcoholic steatohepatitis (NASH). NAFLD and NASH are the fastest-growing liver diseases in the United States and Europe. Patients with NASH are at high risk for further liver damage, including fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). No FDA-approved treatments for NAFLD or NASH are currently available. Interviewed physicians state that they are limited to providing exercise and nutrition advice, using vitamin E, or attempting to recruit patients into clinical trials. A very high unmet need remains for the development of novel treatment for NAFLD and NASH.

This report provides an overview of the NASH market, including a comprehensive analysis of patient populations, current therapies and medical practice, and opportunities for emerging therapies. The findings described in this report derive from detailed interviews with expert U.S. and European specialists, secondary research, and best-in-class epidemiological analysis. This report provides deep insights into this complex and evolving clinical space, and it includes a detailed analysis of specific opportunities for current and emerging therapies, including experts’ views on which unmet needs have not yet been addressed by developers of new therapies.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports